Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Incidence of Nocturia in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Enlargement and Outcomes After Medical Treatment: Results from the Evolution European Association of Urology Research Foundation Prospective Multinational Registry.

Malde S, Patel A, Martínez-Piñeiro L, de la Taille A, Bjartell A, Tubaro A, Witjes W, Caris C.

Eur Urol Focus. 2019 Jul 22. pii: S2405-4569(19)30197-X. doi: 10.1016/j.euf.2019.07.003. [Epub ahead of print]

PMID:
31345783
2.

Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11.

Reza M, Wirth M, Tammela T, Cicalese V, Veiga FG, Mulders P, Miller K, Tubaro A, Debruyne F, Patel A, Caris C, Witjes W, Thorsson O, Wollmer P, Edenbrandt L, Ohlsson M, Trägårdh E, Bjartell A.

Eur Urol Oncol. 2019 Jun 8. pii: S2588-9311(19)30069-0. doi: 10.1016/j.euo.2019.05.002. [Epub ahead of print]

PMID:
31186177
3.

Medical therapy versus transurethral resection of the prostate (TURP) for the treatment of symptomatic benign prostatic enlargement (BPE): a cost minimisation analysis.

Davis NF, Jack GS, Witjes WP, Bjartell A, Caris C, Patel A, de la Taille A, Lawrentschuk N, Bolton DM, Tubaro A.

World J Urol. 2019 May;37(5):873-878. doi: 10.1007/s00345-018-2454-9. Epub 2018 Aug 25.

PMID:
30145778
4.

Adjuvant recMAGE-A3 Immunotherapy After Cystectomy for Muscle-invasive Bladder Cancer: Lessons Learned from the Phase 2 MAGNOLIA Clinical Trial.

Mulders PFA, Martínez-Piñeiro L, Heidenreich A, Babjuk M, Colombel M, Colombo R, Radziszewski P, Korneyev I, Surcel C, Yakovlev P, Witjes JA, Caris C, Schipper R, Witjes WPJ; MAGNOLIA Study Group of the EAU Research Foundation.

Eur Urol Focus. 2019 Sep;5(5):849-852. doi: 10.1016/j.euf.2018.02.005. Epub 2018 Feb 21.

PMID:
29477797
5.

Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).

Wirth M, Tammela T, Cicalese V, Gomez Veiga F, Delaere K, Miller K, Tubaro A, Schulze M, Debruyne F, Huland H, Patel A, Lecouvet F, Caris C, Witjes W.

Eur Urol. 2015 Mar;67(3):482-91. doi: 10.1016/j.eururo.2014.02.014. Epub 2014 Feb 20.

PMID:
24630685
7.

Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial.

Lammers RJ, Witjes WP, Janzing-Pastors MH, Caris CT, Witjes JA.

J Clin Oncol. 2012 Jun 20;30(18):2273-9. doi: 10.1200/JCO.2011.39.2936. Epub 2012 May 14.

PMID:
22585689
8.

Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer.

Lammers RJ, Witjes WP, Hendricksen K, Caris CT, Janzing-Pastors MH, Witjes JA.

Eur Urol. 2011 Oct;60(4):713-20. doi: 10.1016/j.eururo.2011.07.010. Epub 2011 Jul 14.

PMID:
21794974
9.

Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.

Hendricksen K, Witjes WP, Idema JG, Kums JJ, van Vierssen Trip OB, de Bruin MJ, Vergunst H, Caris CT, Janzing-Pastors MH, Witjes JA.

Eur Urol. 2008 May;53(5):984-91. doi: 10.1016/j.eururo.2007.12.033. Epub 2007 Dec 27.

PMID:
18248876
10.

A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life.

van Andel G, Fernandez de Moral P, Caris CT, Carpentier P, Wils J, de Bruin MJ, Witjes JA, Debruyne FM, Witjes WP.

World J Urol. 2003 Aug;21(3):177-82. Epub 2003 Jun 18.

PMID:
12819912
11.

Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression.

Smits G, Schaafsma E, Kiemeney L, Caris C, Debruyne F, Witjes JA.

Urology. 1998 Dec;52(6):1009-13; discussion 1013-4.

PMID:
9836546
12.
13.

Iron mobilisation and cellular protection by a new synthetic chelator O-Trensox.

Rakba N, Aouad F, Henry C, Caris C, Morel I, Baret P, Pierre JL, Brissot P, Ward RJ, Lescoat G, Crichton RR.

Biochem Pharmacol. 1998 Jun 1;55(11):1797-806.

PMID:
9714298
14.

Iron uptake in Ustilago maydis: tracking the iron path.

Ardon O, Nudelman R, Caris C, Libman J, Shanzer A, Chen Y, Hadar Y.

J Bacteriol. 1998 Apr;180(8):2021-6.

15.

Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis.

Witjes WP, Rosier PF, Caris CT, Debruyne FM, de la Rosette JJ.

Urology. 1997 Feb;49(2):197-205; discussion 205-6.

PMID:
9037281
16.
17.

Metabolization of iron by plant cells using O-Trensox, a high-affinity abiotic iron-chelating agent.

Caris C, Baret P, Beguin C, Serratrice G, Pierre JL, Laulhère JP.

Biochem J. 1995 Dec 15;312 ( Pt 3):879-85.

18.

Risk factors in carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.

van Gils-Gielen RJ, Witjes WP, Caris CT, Debruyne FM, Witjes JA, Oosterhof GO.

Urology. 1995 Apr;45(4):581-6.

PMID:
7716838

Supplemental Content

Support Center